A detailed history of Luts & Greenleigh Group, Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Luts & Greenleigh Group, Inc holds 933 shares of LLY stock, worth $699,675. This represents 0.79% of its overall portfolio holdings.

Number of Shares
933
Previous 897 4.01%
Holding current value
$699,675
Previous $812 Million 1.78%
% of portfolio
0.79%
Previous 0.84%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$772.14 - $960.02 $27,797 - $34,560
36 Added 4.01%
933 $827 Million
Q2 2024

Aug 09, 2024

BUY
$724.87 - $909.04 $240,656 - $301,801
332 Added 58.76%
897 $812 Million
Q4 2023

Jan 29, 2024

BUY
$525.19 - $619.13 $34,137 - $40,243
65 Added 13.0%
565 $329 Million
Q3 2023

Nov 01, 2023

BUY
$434.7 - $599.3 $217,350 - $299,650
500 New
500 $268 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $713B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Luts & Greenleigh Group, Inc Portfolio

Follow Luts & Greenleigh Group, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Luts & Greenleigh Group, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Luts & Greenleigh Group, Inc with notifications on news.